Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
David W Miles, Arlene Chan, Luc Y Dirix, et al.
Neoplasia (New York, N.Y.)
|
October 21, 2016
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
Nick Beije, Wendy Onstenk, Jaco Kraan, et al.
Archives of Pathology & Laboratory Medicine
|
December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial
John M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2004
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification
Ilse Van der Auwera, Steven J Van Laere, Gert G Van den Eynden, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer
Gert G Van den Eynden, Marcel Smid, Steven J Van Laere, et al.
Breast Cancer Research and Treatment
|
October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
The Lancet. Oncology
|
July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Marloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer
Ignace B Vergote, Agustin Garcia, John Micha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--letter
Gert G Van den Eynden, Nigel C Bird, Luc Y Dirix, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
David W Miles, Arlene Chan, Luc Y Dirix, et al.
Neoplasia (New York, N.Y.)
|
October 21, 2016
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
Nick Beije, Wendy Onstenk, Jaco Kraan, et al.
Archives of Pathology & Laboratory Medicine
|
December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial
John M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2004
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification
Ilse Van der Auwera, Steven J Van Laere, Gert G Van den Eynden, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer
Gert G Van den Eynden, Marcel Smid, Steven J Van Laere, et al.
Breast Cancer Research and Treatment
|
October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
The Lancet. Oncology
|
July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Marloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer
Ignace B Vergote, Agustin Garcia, John Micha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--letter
Gert G Van den Eynden, Nigel C Bird, Luc Y Dirix, et al.
Page
of 9